


LIVE WEBINAR ON GROWTH DISORDERS

Recognition and Diagnosis





Webinar 3

Indications and potential benefit
of growth hormone therapy

Thursday, 17 February 2022

from 18:00 to 19:00 SGT (*Singapore Time*)

from 11:00 to 12:00 CET



OVERVIEW

The aim of the webinar is to set the scene for modern therapy with recombinant human growth hormone (rhGH). The background to rhGH therapy is discussed from the points of view of historical perspective and potential responses in children with a poor adult height prognosis. Growth disorders which are licensed for therapy are discussed together with the published responses to rhGH. The difference between rhGH therapy as replacement in the GH deficient child and rhGH as a pharmacological agent in non-GH deficiency disorders, such as Turner syndrome and short stature caused by low birth weight, is clearly defined. Manipulation of puberty to gain extra time for growth is explained.

LEARNING OBJECTIVES

At the conclusions of the live webinar 3 “Indications and potential benefit of growth hormone therapy” delegates will understand:

- Differences between true pathological short stature and variants of normal growth as regards hGH therapy
- How did recombinant human GH (rhGH) arise
- The effects of the arrival of rhGH
- Responsiveness to hGH
- Distinction between replacement hGH and the pharmacological effect of hGH
- Growth responses in GH deficiency
- Appraisal of growth responses and prediction of response
- Individualisation of hGH therapy
- Growth responses in Turner syndrome
- Growth responses in the short SGA child
- Prader-Willi syndrome
- What is idiopathic short stature, Growth responses
- Enhancement of responses by manipulation of pubertal development

TARGET AUDIENCE

This activity is designed for pediatricians, pediatric endocrinologists and general practitioners from the Asia Pacific Region.

LANGUAGE

The official language of this live educational conference is English.

REGISTRATION

To access the live webinar, please register by clicking on the below link:

<https://cme-learning.scientificseminars.com/course/indications-and-potential-benefit-of-gh-therapy>

and complete a very short survey covering your current knowledge of the subject matter prior to attending the webinar.

CONTINUING MEDICAL EDUCATION

The **“Indications and potential benefit of growth hormone therapy”, Rome, Italy, 17/02/2022 - 17/02/2022** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **1 European CME credit (ECMEC®)**. Each medical specialist should claim only those hours of credit that he/eshe actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



CME PROVIDER

Scientific Seminars International Foundation

Program Manager: Annamaria Nesticò
T +39 380 1504116 - F +39 06 4827169
info@scientificseminars.com

SCIENTIFIC ORGANIZER AND SPEAKER

Martin O. Savage

Emeritus Professor of Pediatric Endocrinology
The William Harvey Research Institute
Barts and the London School of Medicine & Dentistry,
Queen Mary University of London,
London, United Kingdom



Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He is a clinician with clinical and research interests in growth disorders, specifically those with abnormalities in the growth hormone-IGF-1 axis. His main research field has been the phenotype- genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other clinical interests are Cushing's syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. Professor Savage has lectured in 60 countries worldwide and has published more than 460 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. He continues to lecture nationally and internationally.

THURSDAY, 17 FEBRUARY 2022
FROM 18:00 TO 19:00 SGT (SINGAPORE TIME)

18.00	A	Growth disorders and the perspective of hGH therapy <i>Welcome and introduction</i> • Classification of growth disorders • Which are appropriate for hGH therapy • Importance of commitment to a diagnosis • hGH therapy before recombinant hGH • Effect of recombinant hGH • Range of diagnosis approved for hGH • Difference between replacement and pharmacological effect
18.10	B	Growth responses and predictions of response in different disorders • GH deficiency • Critical appraisal and prediction factors • Individualisation of therapy • Turner syndrome • SGA • Prader-Willi • Idiopathic short stature
18.30	C	Enhancement of growth response by manipulation of puberty development • Oestrogen as the key determinant of adult height and skeletal maturation • Use of GnRH analogues and aromatase inhibitors to prolong growth • Experience in GH deficiency and idiopathic short stature • Summary • Overall conclusions
18.45		Q&A, Interactive discussion with participants
19.00		End of the live webinar

FACULTY DISCLOSURE

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Martin Savage Declared receipt of honoraria or consultation fees from OPKO, Pfizer, Sandoz, Merck Healthcare KGaA Darmstadt, Germany, Springer-Nature IME, Visen and participation in IPSEN and Novo Nordisk speaker's bureau.



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.



Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com

Copyright © Scientific Seminars International Foundation, 2022. All rights reserved.